Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.25.1
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses 841,685 1,068,320
Research and Development Expenses 1,545,513 1,198,938
Stock Based Compensation 84,636 517,365
Loss from Operations (2,471,834) (2,784,623)
Other (Income) Expenses    
Interest and Dividend Income (62,512) (18,306)
Gain on Sale of Investments (2,176) (175)
Unrealized Loss on Marketable Securities 1,597 899
Change in fair value of Derivative Liabilities (1,284,000) (61,000)
Change in fair value of Warrant Liabilities 7,094,000
Total Other (Income) Expenses (1,347,091) 7,015,418
Loss Before Income Tax (1,124,743) (9,800,041)
Income Tax Benefit
Net Loss (1,124,743) (9,800,041)
Preferred Stock Dividends 813,496 1,201,867
Net Loss Attributable to Common Stockholders $ (1,938,239) $ (11,001,908)
Basic net loss per common share $ (0.36) $ (5.14)
Diluted net loss per common share $ (0.36) $ (5.14)
Weighted average basic common stock outstanding 5,349,662 2,141,131
Weighted average diluted common stock outstanding 5,349,662 2,141,131